Literature DB >> 8562936

Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.

D Chauhan1, H Uchiyama, Y Akbarali, M Urashima, K Yamamoto, T A Libermann, K C Anderson.   

Abstract

Adhesion of multiple myeloma (MM) cells to bone marrow stromal cells (BMSCs) not only localizes MM cells in the marrow microenvironment, but also triggers interleukin-6 (IL-6) secretion by BMSCs and related MM cell proliferation. In the present study, we characterized the regulation of IL-6 gene expression in BMSCs during MM cell adhesion. Adhesion of ARH-77, HS-Sultan, IM-9, and U266 MM cell lines to BMSCs and BMSC lines (LP 101 and AA 101) triggered 5-through 15-fold and 2-through 4-fold increases in IL-6 secretion, respectively. IL-6 mRNA transcripts were undetectable by Northern blotting in IM-9 MM cells or LP 101 BMSCs cultured alone; however, adherence of IM-9 cells to LP 101 cells induced a transient increase in IL-6 transcripts at 6 hours, followed by peak IL-6 secretion at 24 hours. To confirm increased IL-6 transcription and characterize its regulation, LP101 BMSCs were transiently transfected with full length and deletion fragments of the IL-6 promoter linked to the chloramphenicol acetyltransferase (CAT) reporter gene. Transient transfection of LP101 BMSCs with plasmid containing an intact NF-kappa B site showed a 6.8 +/- 0.4-fold increase in CAT activity triggered by IM-9 MM cell adhesion (n = 3, P < .05). Transfection of LP 101 cells with plasmid containing a single base pair deletion from the NF-kapp B binding motif abolished the MM adhesion-induced increase in CAT activity, whereas transfection with plasmid containing three copies of synthetic NF-kappa B sequence resulted in an 8.1 +/- 0.7-fold increase in CAT activity related to MM adhesion (n = 3, P < .05). These data suggest that the NF-kappa B site is one of the essential regulatory elements for MM cell adhesion-induced IL-6 transcription in BMSCs. Electrophoretic mobility shift assays confirmed the involvement of NF-kappa B activation in regulating MM adhesion-induced IL-6 transcription in BMSCs. Further characterization of the upstream events in the signalling cascade regulating IL-6 may not only delineate mechanisms of IL-6 regulation during paracrine MM cell growth, but also provide new therapeutic strategies based on interruption of IL-6 mediated tumor cell growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8562936

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  162 in total

Review 1.  Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

Authors:  Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2011-11       Impact factor: 6.261

Review 2.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

3.  Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.

Authors:  Dharminder Chauhan; Madhavi Bandi; Ajita V Singh; Arghya Ray; Noopur Raje; Paul Richardson; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2011-09-26       Impact factor: 6.998

4.  Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency.

Authors:  C Miyaura; Y Onoe; M Inada; K Maki; K Ikuta; M Ito; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

5.  Hypoxia-induced secretion of IL-10 from adipose-derived mesenchymal stem cell promotes growth and cancer stem cell properties of Burkitt lymphoma.

Authors:  Lihua Xu; Xu Wang; Jiani Wang; Dan Liu; Yaya Wang; Zhenqian Huang; Huo Tan
Journal:  Tumour Biol       Date:  2015-12-23

Review 6.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 7.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

Review 8.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.

Authors:  Dharminder Chauhan; Arghya Ray; Kristina Viktorsson; Jack Spira; Claudia Paba-Prada; Nikhil Munshi; Paul Richardson; Rolf Lewensohn; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2013-04-12       Impact factor: 12.531

10.  The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.

Authors:  Robert O'Connor; Melissa G Ooi; Justine Meiller; Jana Jakubikova; Steffen Klippel; Jake Delmore; Paul Richardson; Kenneth Anderson; Martin Clynes; Constantine S Mitsiades; Peter O'Gorman
Journal:  Cancer Chemother Pharmacol       Date:  2013-04-16       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.